A Phase II, Randomized, Observer-Blind With Single-Blind Booster, Multi-Center, Study to Evaluate Safety, Tolerability and Immunogenicity of an Adjuvanted Cell Culture-Derived H5N1 Subunit Influenza Virus Vaccine at Two Different Formulations in Healthy Adult Subjects.

Trial Profile

A Phase II, Randomized, Observer-Blind With Single-Blind Booster, Multi-Center, Study to Evaluate Safety, Tolerability and Immunogenicity of an Adjuvanted Cell Culture-Derived H5N1 Subunit Influenza Virus Vaccine at Two Different Formulations in Healthy Adult Subjects.

Completed
Phase of Trial: Phase II

Latest Information Update: 09 Feb 2015

At a glance

  • Drugs Influenza A virus vaccine-H5N1 (Primary)
  • Indications Influenza A virus H5N1 subtype
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Novartis Vaccines
  • Most Recent Events

    • 24 Jun 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 25 Jun 2013 Planned End Date changed from 1 Apr 2015 to 1 May 2014 as reported by ClinicalTrials.gov.
    • 25 Jun 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top